<DOC>
	<DOC>NCT01089725</DOC>
	<brief_summary>This is an efficacy and safety study of 3 doses (2.5 mg, 5 mg and 10mg) of tanezumab administered subcutaneously versus placebo. This study will also compare a subcutaneous (SC) administration of 10 mg of tanezumab) with an intravenous (IV) administration of 10 mg of tanezumab. Each person will receive an IV infusion and a SC infusion. The study will last 16 weeks for those who wish to enter a 64-week extension study or 24 weeks for those who do not.</brief_summary>
	<brief_title>Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study</brief_title>
	<detailed_description>This study was terminated on 08 Nov 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Diagnosis of osteoarthritis (OA) of the knee according to American College of Rheumatology (ACR) criteria with a Kellgren Lawrence score of greater than or equal to 2 18 years of age or greater Two methods of birth control one of which must be barrier if of childbearing potential Willing to discontinue pain medication except as permitted per protocol Pregnancy or wishing to be pregnant during the course of the study, lactating women Body Mass Index (BMI) greater than 39 Clinically significant cardiac, neurological, psychiatric conditions and other conditions that are excluded by the protocol. Previous exposure to a Nerve Growth Factor (NGF) antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>parallel group</keyword>
	<keyword>double-blind</keyword>
	<keyword>multicenter</keyword>
	<keyword>injection</keyword>
	<keyword>infusion</keyword>
	<keyword>osteoarthritis</keyword>
	<keyword>bridging</keyword>
	<keyword>subcutaneous</keyword>
	<keyword>intravenous</keyword>
	<keyword>tanezumab</keyword>
</DOC>